187 related articles for article (PubMed ID: 36715053)
1. Musculoskeletal Ultrasound in Monitoring the Efficacy of Gout: A Prospective Study Based on Tophus and Double Contour Sign.
Yuan H; Fan Y; Mou X; Qing Y; Yan X; Tang X; Yue W; Gu P; Yang Q; He Y
Balkan Med J; 2023 Mar; 40(2):104-110. PubMed ID: 36715053
[TBL] [Abstract][Full Text] [Related]
2. Ultrasound Evaluation of Three Outcome Domains in the Follow-up of Urate-Lowering Therapy in Gout: An Observational Study.
Zhang W; Zhao D; Wu M; Chen W; Jin Z; Zhang H
Ultrasound Med Biol; 2021 Jun; 47(6):1495-1505. PubMed ID: 33785225
[TBL] [Abstract][Full Text] [Related]
3. The value of musculoskeletal ultrasound in predicting gout flares in index joints: A prospective cohort study of people with gout starting urate-lowering therapy.
Han L; Li R; Dalbeth N; Liu M; Yu Q; Jiang C; Ning C; Liu Z; He Y; Li M; Xue X; Jia F; Jia Z; Sun W; Zhang H; Lu J; Wang C; Li C
Semin Arthritis Rheum; 2024 Aug; 67():152418. PubMed ID: 38422901
[TBL] [Abstract][Full Text] [Related]
4. Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy.
Christiansen SN; Østergaard M; Slot O; Keen H; Bruyn GAW; D'Agostino MA; Terslev L
RMD Open; 2020 Jan; 6(1):. PubMed ID: 32396518
[TBL] [Abstract][Full Text] [Related]
5. Retrospective longitudinal assessment of ultrasound gout lesions using the OMERACT semi-quantitative scoring system.
Christiansen SN; Østergaard M; Slot O; Fana V; Terslev L
Rheumatology (Oxford); 2022 Nov; 61(12):4711-4721. PubMed ID: 35298610
[TBL] [Abstract][Full Text] [Related]
6. The Role of Ultrasound in Evaluating the Effect of Urate-lowering Drugs in Gout Patients.
El-Mallah R; Ibrahim RA; El Attar EA
Curr Rheumatol Rev; 2022; 18(4):338-345. PubMed ID: 36268549
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study.
Ebstein E; Forien M; Norkuviene E; Richette P; Mouterde G; Daien C; Ea HK; Brière C; Lioté F; Petraitis M; Bardin T; Ora J; Dieudé P; Ottaviani S
Rheumatology (Oxford); 2019 Mar; 58(3):410-417. PubMed ID: 30285127
[TBL] [Abstract][Full Text] [Related]
8. UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis.
Ebstein E; Forien M; Norkuviene E; Richette P; Mouterde G; Daien C; Ea HK; Brière C; Lioté F; Petraitis M; Bardin T; Ora J; Dieudé P; Ottaviani S
Joint Bone Spine; 2020 Dec; 87(6):647-651. PubMed ID: 32979555
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of the value of ultrasound and magnetic resonance musculoskeletal imaging in the evaluation of response to treatment of gout.
Villaverde V; Rosario MP; Loza E; Pérez F
Reumatol Clin; 2014; 10(3):160-3. PubMed ID: 24296268
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking.
Modjinou DV; Krasnokutsky S; Gyftopoulos S; Pike VC; Karis E; Keenan RT; Lee K; Crittenden DB; Samuels J; Pillinger MH
Clin Rheumatol; 2017 Sep; 36(9):2101-2107. PubMed ID: 28623421
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of ultrasound-detected tophi in patients with gout.
Lu B; Lu Q; Huang B; Li C; Zheng F; Wang P
Clin Rheumatol; 2020 Jun; 39(6):1953-1960. PubMed ID: 32062769
[TBL] [Abstract][Full Text] [Related]
12. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
Baraf HS; Becker MA; Gutierrez-Urena SR; Treadwell EL; Vazquez-Mellado J; Rehrig CD; Ottery FD; Sundy JS; Yood RA
Arthritis Res Ther; 2013 Sep; 15(5):R137. PubMed ID: 24286509
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound for the diagnosis of gout-the value of gout lesions as defined by the Outcome Measures in Rheumatology ultrasound group.
Christiansen SN; Østergaard M; Slot O; Fana V; Terslev L
Rheumatology (Oxford); 2021 Jan; 60(1):239-249. PubMed ID: 32696059
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound sensitivity to changes in gout: a longitudinal study after two years of treatment.
Peiteado D; Villalba A; Martín-Mola E; Balsa A; De Miguel E
Clin Exp Rheumatol; 2017; 35(5):746-751. PubMed ID: 28281462
[TBL] [Abstract][Full Text] [Related]
15. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
Mandell BF; Yeo AE; Lipsky PE
Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
[TBL] [Abstract][Full Text] [Related]
16. The Tophus Impact Questionnaire (TIQ-20): responsiveness to change during urate-lowering therapy.
Cao C; Gamble G; Horne A; Aati O; Doyle A; Drake J; Stamp LK; Dalbeth N
Rheumatology (Oxford); 2024 May; 63(6):1539-1542. PubMed ID: 37688559
[TBL] [Abstract][Full Text] [Related]
17. Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study.
Pascart T; Grandjean A; Norberciak L; Ducoulombier V; Motte M; Luraschi H; Vandecandelaere M; Godart C; Houvenagel E; Namane N; Budzik JF
Arthritis Res Ther; 2017 Jul; 19(1):171. PubMed ID: 28732526
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound in gout: a useful tool for following urate-lowering therapy.
Ottaviani S; Gill G; Aubrun A; Palazzo E; Meyer O; Dieudé P
Joint Bone Spine; 2015 Jan; 82(1):42-4. PubMed ID: 25543275
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for the formation of double-contour sign and tophi in gout.
Sun C; Qi X; Tian Y; Gao L; Jin H; Guo H
J Orthop Surg Res; 2019 Jul; 14(1):239. PubMed ID: 31358044
[TBL] [Abstract][Full Text] [Related]
20. Ultrasound and clinical features of hip involvement in patients with gout.
Di Matteo A; Filippucci E; Cipolletta E; Musca A; Di Donato E; Martire V; Jesus D; Salaffi F; Grassi W
Joint Bone Spine; 2019 Oct; 86(5):633-636. PubMed ID: 30779966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
